Evoke Pharma, Inc.

Evoke Pharma, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. Evoke Pharma, Inc. is not a good value stock. Evoke Pharma, Inc. is not very popular among insiders. Evoke Pharma, Inc. is a mediocre stock to choose.
Log in to see more information.
Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the tr...
EVOK Fundamental Data by TradingView

News

Evoke Pharma to Participate in Gastroenterology and Hepatology Advanced Practice Providers (GHAPP) Annual Conference
Evoke Pharma to Participate in Gastroenterology and Hepatology Advanced Practice Providers (GHAPP) Annual Conference

Globe Newswire SOLANA BEACH, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases...\n more…

Evoke Pharma (NASDAQ:EVOK) Receives New Coverage from Analysts at StockNews.com
Evoke Pharma (NASDAQ:EVOK) Receives New Coverage from Analysts at StockNews.com

Zolmax Equities research analysts at StockNews.com started coverage on shares of Evoke Pharma (NASDAQ:EVOK - Get Free Report) in a report issued on Monday. The firm set a "sell" rating on the specialty...\n more…

Evoke Pharma to Present at H.C. Wainwright's 26th Annual Global Investment Conference
Evoke Pharma to Present at H.C. Wainwright's 26th Annual Global Investment Conference

Globe Newswire SOLANA BEACH, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases...\n more…

Evoke Pharma (NASDAQ:EVOK) Coverage Initiated by Analysts at StockNews.com
Evoke Pharma (NASDAQ:EVOK) Coverage Initiated by Analysts at StockNews.com

Ticker Report StockNews.com initiated coverage on shares of Evoke Pharma (NASDAQ:EVOK - Free Report) in a research note issued to investors on Sunday morning. The firm issued a sell rating on the specialty...\n more…

Evoke Pharma files $50M mixed securities shelf
Evoke Pharma files $50M mixed securities shelf

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Evoke Pharma (NASDAQ:EVOK) Coverage Initiated at StockNews.com
Evoke Pharma (NASDAQ:EVOK) Coverage Initiated at StockNews.com

Zolmax Equities researchers at StockNews.com initiated coverage on shares of Evoke Pharma (NASDAQ:EVOK - Get Free Report) in a research note issued on Saturday. The firm set a "sell" rating on the specialty...\n more…